Eocene Ltd.(EOCN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.48
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for EOCN

11/13/2026: EOCN (1-star) is currently NOT-A-BUY. Pass it for now.

Eocene Ltd. is a micro-cap medical technology and biopharmaceutical company focused on gastrointestinal disease management, surgical devices, and metabolic therapeutics. The company's key strengths include its innovative CG-100 intraluminal bypass device—which holds FDA Breakthrough Designation—and its clinical pipeline asset Aramchol. Its primary investment story centers on expanding commercial adoption for its surgical devices internationally while advancing clinical evaluations in liver and oncology indications. However, the company faces substantial execution, competitive, and financing risks given its limited revenue scale and historical operating losses. Eocene is best suited for speculative or momentum-oriented investors willing to monitor clinical milestones, regulatory updates, and early international sales progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitWhile operating in high-growth healthcare sectors, the company currently lacks consistent revenue scale and predictable commercial growth.
Momentum investorStrong fit while signal remains positiveMicro-cap clinical stocks can experience sharp, event-driven momentum spikes upon positive trial or distribution announcements.
Value investorWeak fitThe lack of positive earnings, cash flow generation, and commercial maturity makes traditional fundamental value assessment challenging.
Dividend investorWeak fitEocene does not pay dividends and retains all capital for clinical and commercial development.
Low-risk investorWeak fitHigh clinical, regulatory, financial volatility and micro-cap liquidity risks expose investors to substantial capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading float and micro-cap status result in sharp intraday and periodic price swings.
Valuation riskHighValuation depends heavily on binary clinical and commercial milestones rather than predictable earnings.
Competition risk (biopharma and medtech competition)HighThe company competes against well-funded medical device and pharmaceutical enterprises.
Business qualityMediumThe company possesses innovative assets like FDA-designated devices, but lacks commercial scale.
Dividend incomeLow / noneNo dividend distributions are paid or anticipated.
Execution riskHighSuccess relies entirely on executing clinical trials, gaining regulatory approvals, and building sales channels.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.65M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 7.8K shares
Beta 0.72
52 Weeks Range 2.05 - 12.32
Updated Date 11/15/2026
52 Weeks Range 2.05 - 12.32
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -15.33

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -66.39%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
EOCN receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
EOCN has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-37.1%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
EOCN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
EOCN's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-37.1%, negative) and free-cash-flow growth (-7.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.4% (soft) and 91.5% of outstanding shares are publicly tradable (strong). Insider ownership of 3.04% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Citadel Advisors Llc 1.04%
HRT FINANCIAL LLC 0.51%
XTX Topco Ltd 0.18%
TWO SIGMA SECURITIES, LLC 0.13%
Royal Bank of Canada 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
EOCN generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
EOCN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical DevicesCommercial sales and initial distribution of the CG-100 intraluminal bypass device through subsidiary Colospan.Early-stage commercial device sales intended to build international traction in Europe and overseas.
Biopharmaceutical Licensing & DevelopmentPotential milestone payments, upfront fees, and licensing royalties from clinical drug candidates like Aramchol.Long-term value creation tied to successful drug development partnerships or commercial licensing agreements.
Geographic ExposureOperations centered in Israel, with commercial expansion efforts extending into European and U.S. clinical markets.Exposes the business to international regulatory frameworks and cross-border commercial partnerships.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -8.45M
Price to Sales(TTM) -
Enterprise Value -8.45M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.32
Shares Outstanding 1.07M
Shares Floating 977.02K
Shares Outstanding 1.07M
Shares Floating 977.02K
Percent Insiders 3.04
Percent Institutions 1.38

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.